EXACT Sciences Corporation (EXAS): Price Target and June Short Interest Disclosure

EXACT Sciences Corporation (EXAS) : Currently there are 9 street experts covering EXACT Sciences Corporation (EXAS) stock. The most bullish and bearish price target for the stock is $18 and $7 respectively for the short term. The average price target of all the analysts comes to $11.83. The estimated standard deviation from the target is $3.81.

The short interest in EXACT Sciences Corporation (EXAS) has increased from 20,950,888 on June 15,2016 to 31,525,866 on June 30,2016. The change was measured at 10,574,978 shares or 50.5%. The leftover shorts were 33% of the floated shares. The days to cover are 3, given the average daily volume of 9,866,015 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, In a research note released to the investors, Craig-Hallum upgrades its rating on EXACT Sciences Corporation (NASDAQ:EXAS).The analysts at the brokerage house have a current rating of Buy on the shares. Earlier, the shares were rated a Hold by the brokerage firm. In a recent information released to the investors, Craig-Hallum raises the price target of $18 per share. The rating by the firm was issued on June 16, 2016.


EXACT Sciences Corporation (NASDAQ:EXAS): On Thursdays trading session , Opening price of the stock was $13.2 with an intraday high of $13.2794. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $12.51. However, the stock managed to close at $12.81, a loss of 2.21% for the day. On the previous day, the stock had closed at $13.1. The total traded volume of the day was 2,708,288 shares.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.